Phase I Dose Escalation/Dose Expansion Trial of NBTXR3/SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of Anti-PD-1 Naïve or Resistant Patients with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaC. Shen, A.J. Rosenberg, Ammar Sukari et al.|International Journal of Radiation Oncology*Biology*Physics|2025Cited by 1